Granulocyte-colony stimulating factors (G-CSFs) are commonly employed in clinical practice. The most relevant adverse event of G-CSF administration is bone pain. Approximately 20% of cancer patients experienced bone pain with the administration of prophylactic daily G-CSFs (lenograstim and filgrastim). The reported incidence of bone pain in cancer patients undergoing pegfilgrastim prophylaxis ranged from 25% to 38%. In healthy donors the incidence of bone pain was higher than in cancer patients, ranging from 52% to 84%. There are four main causes of G-CSF related bone pain: bone marrow quantitative and qualitative expansion, peripheral nociceptor sensitization to nociceptive stimuli, modulation of immune function and direct effect on bone metabolism. For the prevention and treatment of bone pain occurring after or during GCSFs administration, acetaminophen and nonsteroidal anti-inflammatory agents are commonly used as first-line treatment; antihistamines, opioids and dose reduction of G-CSFs are considered as second line therapy. The only randomized clinical trial conducted for the prevention and treatment of G-CSF induced bone pain showed the efficacy of naproxen in reducing the incidence, the severity and the duration of bone pain induced by the administration of pegfilgrastim. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)

Lambertini M;Del Mastro L;Bellodi A;
2014-01-01

Abstract

Granulocyte-colony stimulating factors (G-CSFs) are commonly employed in clinical practice. The most relevant adverse event of G-CSF administration is bone pain. Approximately 20% of cancer patients experienced bone pain with the administration of prophylactic daily G-CSFs (lenograstim and filgrastim). The reported incidence of bone pain in cancer patients undergoing pegfilgrastim prophylaxis ranged from 25% to 38%. In healthy donors the incidence of bone pain was higher than in cancer patients, ranging from 52% to 84%. There are four main causes of G-CSF related bone pain: bone marrow quantitative and qualitative expansion, peripheral nociceptor sensitization to nociceptive stimuli, modulation of immune function and direct effect on bone metabolism. For the prevention and treatment of bone pain occurring after or during GCSFs administration, acetaminophen and nonsteroidal anti-inflammatory agents are commonly used as first-line treatment; antihistamines, opioids and dose reduction of G-CSFs are considered as second line therapy. The only randomized clinical trial conducted for the prevention and treatment of G-CSF induced bone pain showed the efficacy of naproxen in reducing the incidence, the severity and the duration of bone pain induced by the administration of pegfilgrastim. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
File in questo prodotto:
File Dimensione Formato  
bjc20142a.pdf

accesso chiuso

Descrizione: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution- NonCommercial-Share Alike 3.0 Unported License.
Tipologia: Documento in versione editoriale
Dimensione 204.59 kB
Formato Adobe PDF
204.59 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/890313
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 92
  • ???jsp.display-item.citation.isi??? 87
social impact